News tagged with 'Cox-2 Inhibitors'

While U.S. litigation against Merck over the drug Vioxx is winding down, in Canada it's heating up. A Saskatchewan class action cannot be established says a three judge panel, but Ontario says this action means the more than one million Canadians, who allege harm from Vioxx, can join in one national class action. 

Even though Vioxx and Bextra have been taken off the market because of a link to stroke and heart attack, a post-withdrawl study confirms the Cox-2 inhibitors increased the risk for stroke among Vioxx users by 28 percent and among Bextra users 41 percent when compared to the control group.